ELANE and alpha 1-antitrypsin deficiency: Moreover, the reduction in inflammatory markers can also be indicative of the therapy’s effectiveness in mitigating the proteolytic damage caused by neutrophil elastase, which is typically unopposed in AATD patients due to low A1AT levels.